REGENXBIO to Participate in Upcoming Investor Conferences

RGNX 11.04.2024

Full Press ReleaseSEC FilingsOur RGNX Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
  • 01.13.2025 - AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
  • 12.16.2024 - Ellie Merle

Recent Filings

  • 01.14.2025 - 4/A Statement of changes in beneficial ownership of securities
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.14.2025 - 8-K Current report

ROCKVILLE, Md.,Nov. 4, 2024/PRNewswire/ --REGENXBIO Inc.(Nasdaq: RGNX) today announced it will participate in the following investor conferences:

UBS Global Healthcare ConferenceFireside Chat:Wednesday, November 13at12:30 p.m. PTLocation:Rancho Palos Verdes, CA

Stifel 2024 Healthcare ConferenceFireside Chat:Tuesday, November 19at11:30 a.m. ETLocation:New York, NY

Piper Sandler 36th Annual Healthcare ConferenceFireside Chat:Thursday, December 5at9:30 a.m. ETLocation:New York, NY

Live webcasts of the fireside chats can be accessed in the Investors section ofREGENXBIO'swebsite atwww.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUTREGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma®for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visitWWW.REGENXBIO.COM.

Contacts:

Dana CormackCorporate Communicationsdcormack@regenxbio.com

Investors:George E. MacDougallInvestor RelationsIR@regenxbio.com

(PRNewsfoto/REGENXBIO Inc.)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302294648.html

SOURCEREGENXBIO Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com